Keros Therapeutics Q2 net loss narrows on lower expenses

The current average analyst rating on the shares is buy, with 4 strong buy or buy ratings, 4 hold ratings and no sell or strong sell ratings.

The average consensus recommendation for the biotechnology and medical research peer group is buy. Wall Street's median 12-month price target for Keros Therapeutics Inc is $20.00, about 98.6% above its July 31 closing price of $10.07.

• R&D spend declined sharply due to the transition of elritercept-related research and development to Takeda and corporate restructuring.
• General and administrative expenses fell because of reduced professional fees and compensation costs following the 2025 restructuring.

Keros said it began a Phase 2 trial of rinvatercept in Duchenne muscular dystrophy (DMD).